After decades of hype and setbacks, scientists have made impressive progress into tricking stem cells into repairing organs.

Rein Therapeutics has initiated the randomised RENEW Phase II trial of its Caveolin-1-related peptide, LTI-03, targeting ...

These stem cells, known as type 2 alveolar epithelial cells (AEC2s), play a key role in repairing lung tissue. Without ...

Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines ...

Ipilimumab, a cancer immunotherapy, reduced scar formation and promoted tissue regeneration in a mouse model of idiopathic ...

Rein Therapeutics has begun screening and recruiting patients for its renew phase 2 trial, assessing LTI-03 as a potential ...

Rein Therapeutics initiates RENEW phase 2 trial of LTI-03 in patients with idiopathic pulmonary fibrosis: Austin, Texas Tuesday, May 13, 2025, 18:00 Hrs [IST] Rein Therapeutics (R ...

Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and ...